For an optimally cytoreduced, stage III ovarian carcinosarcoma, would you offer bevacizumab maintenance after completion of adjuvant carboplatin/taxol?
Patient is currently cycle 5/6 of carboplatin/taxol and tolerating well, has received no bevacizumab.
Community PollStarted
What is your maintenance strategy for Stage III optimally debulked ovarian carcinosarcoma patient?
27 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
Answered on
For an optimally cytoreduced patient with Stage III ovarian carcinosarcoma, I would not add bevacizumab unless the patient was "optimal" at interval surgery and had neoadjuvant and adjuvant use of bevacizumab with chemo and then to be continued in maintenance. The use of bevacizumab with chemo in th...
Join for free or sign in to see the full answer